SOURCES SOUGHT
65 -- Standardization of Safety Needles for the Pacific Region, TRBO Region 12, a military integrated network comprised of 18 Army, Navy, Air Force, and Marine Corps medical treatment facilities in Hawaii, Guam, Japan, Okinawa, and Korea
- Notice Date
- 3/5/2008
- Notice Type
- Sources Sought
- NAICS
- 423450
— Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers
- Contracting Office
- Pacific Regional Contr Ofc TAMC, ATTN: MCAA PC BLDG 160, 160 Krukowski Road, Honolulu, HI 96859-5000
- ZIP Code
- 96859-5000
- Solicitation Number
- W81K02-08-T-3015
- Response Due
- 3/27/2008
- Archive Date
- 5/26/2008
- Point of Contact
- Susan Hwang, 808-433-3686
- E-Mail Address
-
Email your questions to Pacific Regional Contr Ofc TAMC
(susan.hwang@amedd.army.mil)
- Small Business Set-Aside
- N/A
- Description
- 65-Medical Supplies-Potential Sources Sought --------------- A. General Information The Pacific Region-TRBO Region 12, a military integrated delivery network, comprised of 18 Army, Navy, Air Force, and Marine Corps medical treatment fac ilities in Hawaii, Guam, Japan, Okinawa, and Korea announces a Request for Regional Incentive Agreement Quotation (RFRIAQ) for the standardization of Safety Needles. The primary objective of this program is to standardize the quality of care across the region based on a best value determination that represents the clinically preferred product or source(s) at the best possible price. It is also intended that standardized products be obtained through the Department of Defense Prime Vendor Program. The major facilities in the region include Tripler Army Medical Center, U.S. Naval Hospital Okinawa, U.S. Naval Hospital Guam, U.S. Naval Hospital Yokosuka, 121st Combat Support Hospital Seoul, 374th Medical Group, Yokota AB, and 18th Medical Group Kad ena AB. This standardization action is part of the Medical/Surgical Prime Vendor program executed by the Defense Supply Center Philadelphia (DSCP), Directorate of Medical Materiel. In order to participate, your company must have a Distribution and P ricing Agreement (DAPA) and a separate commercial agreement with the Prime Vendors for the program. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow Prime Vendors to distribute their products. This RFRIAQ is a supplement to the Prime Vendor Program and is not a contract. For additional information regarding DSCPs Prime vendor program, please access their web site at https://dmmonline.dscp.dla.mil The resulting Regional Incentive Agreement ( RIA) will be for a base period of two years (24 months) from date of selection with three 12-month option periods. Anticipated selection date is November 2008. The evaluation will be based on clinical, technical, and pricing factors. The Technical/Company and Clinical/Performance evaluation factors, when combined are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determine d utilizing Best value/ trade off criteria. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, The Government reserves the right to make two or more selections for RIAs. In this event , selection would be based on a combination of MTF preference and product availability. Point of Contact Susan Hwang, TRBO Team Leader 808-433-3686, susan.hwang@amedd.army.mil Cheryl Janus, RN, TRBO Clinical Analyst 808-433-7985, ch eryl.janus@amedd.army.mil B. Products & Performance Required The Pacific Region is seeking product line items in the category of Safety Needles, which at a minimum includes the high volume line items below. Within this region, this product line has an estimated annual dollar requirement of $126,120. This forecast is based on historical prime vendor sales during a recent 12-month period. The top high volume usage lines for this project include are listed in the technical/company criteria.<BR > At the request of the Pacific Region Military Treatment Facilities, vendors will provide educational resources and tools for clinical use of the product, conversion information, prime vendor order numbers, and itemization of the brands, types, and pac kaging information of the products supplied by the vendor. C. Instructions to Vendors DAPA holders interested in participating in this standardization initiative should email their (1) Company name and address, (2) POC (Name and Phone Number, Fax Number, and E-mail address) to susan.hwang@amedd.army.mil AND cheryl.janus@amedd.army.mil. Submissions must be received by 4:00 p.m. Hawaii Standard Time ( HST) on the specified closing date/time of this solicitation. Vendors that fail to meet this submittal deadline will result be disqualified from participating. This process will include vendor requirements to provide electronic responses to techni cal criteria, no charge samples for clinical evaluation, product literature, education and training materials, and submission of electronic best price quotes. Due to the potential for email to be lost in transmission from network security, etc., vendors ar e strongly encouraged to confirm with the Regional POC stated above that their initial submission, quotes, and literature or other requested information has actually arrived at the Regional Tri-Service Business Office (TRBO) via email. Each submitting vend or is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. D. Evaluation Criteria The Tri-Service Product Review Board (TPRB) is the governing body of the standardization process. This board includes clinicians and logisticians from the Military Treatment Facilities within the Pacific Region. They are the deciding officials for this initiative. The Region intends to evaluate price quotes and select a vendor or vendor(s), without discussions. Vendor quotes should contain the vendor's best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendor's best responses to all technical an d/or company questions listed in this announcement. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Pacific Region). Add itionally, the Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down-selection is made during the evaluation process, the Region may limit the number of quotes to the greatest number tha t will permit an efficient competition among vendors. Phase I: Technical/Company Evaluation Process Interested vendors are to respond to this FBO announcement by e-mailing their intent to participate to the above POC by the required response da te. Based on vendor responses, the TRBO POC will request detailed responses to the technical/company criteria from each vendor. Vendors are required to meet/provide responses to the technical/company criteria stated below. All technical/company criteria ar e weighted equally. The responses will be reviewed under the purview of the TPRB to determine the acceptability of each vendor. After the review of the technical/company criteria, those vendors who meet these criteria will be qualified/invited to participa te in the clinical/performance evaluation. Acceptability for purposes of evaluation of technical/company criteria: Generally, responses to all questions in this section demonstrate: (1) the business concern submitting the quote is a distributor or manufacturer of a complete line of the subject medical/surgical consumables; (2) based on the vendors responses, the evaluators have reasonable confidence that the line or products and/or services submitted meet the medical standards of care of the commun ity, applicable to such products or services; (3) the vendor has or is obtaining a DAPA for the items (vendors that fail to have a DAPA will be disqualified); (4) the vendor has, or is obtaining, an agreement covering the items with Cardinal Health, the Pr ime Vendor for the region (vendors whose products are not available through the regional PV will be disqualified); (5) the vendor intends to provide discounts off DAPA for all products included in this standardization initiative (vendors that fail to provi de a discount from DAPA will be disqualified); and (6) the vendors information provided is factually correct. Any misrepresentation of information will disqua lify the vendor from further consideration. The following Technical/Evaluation Criteria have been established for this standardization initiative: 1. Vendor must manufacture and/or distribute a complete product line of Safety Needles. A comp lete line of product is defined as the MTFs requirements for usage items in the product line. Usage items are defined in the Medical/Surgical Prime Vendor contract statement of work as DAPA items ordered at least once per month, and at least one unit per order. Provide certification of all brands of this product line that you manufacturer or distribute with the initial submittal. At a minimum, the following items are required: Safety Needle 18 gauge 1 ? inch, Safety Needle 25 gauge 1 inch, and Safety Needl e 23 gauge 1 inch. 2. Vendors must have a DAPA or be in the process of applying for a DAPA number for the Safety Needles product line. Provide the DAPA number or proof of the application process with the initial submittal. (Note that vendors that fail t o have a DAPA or show a lack of progress in obtaining a DAPA will be disqualified). 3. Vendors must have a separate agreement with the regional prime vendor Cardinal Health for distribution in this Region and provide certification of this with the initi al submittal. (Note that vendors whose products are not available through the regional PV will be disqualified). 4. Vendors must provide discounts off DAPA for all products included in this standardization initiative. Where lower FSS prices are availab le, DAPA holders are required by previous agreement to provide the FSS price as their DAPA price. Therefore, FSS prices do not represent a discount off DAPA. (Note that vendors that fail to provide a discount from DAPA will be disqualified). 5. Vendor m ust provide educational tools, product literature, and materials for Safety Needles as well as no cost samples for the evaluation. Describe your available company educational tools and material resources with the initial submittal. 6. Vendor must provid e customer service (telephonic and e-mail) for regional facilities. Identify company resources and capabilities for such support with the initial submittal. 7. Vendors product line must be latex free and indicated on the packaging and in the product li terature. 8. Vendor will provide a product and packaging which clearly displays the size of the device. Phase II: Clinical/Performance Evaluation Process The multi-disciplinary TPRB Clinical Team will request samples (no charge) from the prod uct line to be clinically evaluated at select Military Treatment Facilities. Vendors are required to ship their no cost samples directly to the designated MTFs and will be allowed 21 calendar days from the date of notification to complete the delivery. Sam ples must be shipped to arrive at the MTF by COB, 4:00 p.m. local time, on the (21st ) calendar day after the notice to ship. Vendors failing to deliver by the deadline will be disqualified from further consideration in the standardization process. <BR >Specific MTFs will evaluate the clinical/performance criteria using a Likert scale, with a one to five rating. One (1) = strongly disagree, Two (2) = disagree, Three (3) = neutral, Four (4) = agree, and Five (5) = strongly agree. All clinical/performance criteria are equally weighted. To determine acceptability, the TPRB Clinical Team comprised of medical professionals from multiple disciplines will evaluate the products based on the evaluation criteria below. The TPRB Clinical Team intends to cond uct the clinical evaluation in a clinical and/or non-clinical The Government reserves the right to conduct evaluations in either a non-clinical or clinical setting or both. The following Clinical/Performance Evaluation Criteria have been establishe d for this standardization initiative: 1. Safety mechanism is easily activated using only one hand.(The mechanism lever or switch or shield can be pushed or pulled or pressed easily by one hand two hands are not necessary to activate the safety mechanism) 2. The safety mechanism cannot be activated passively.(The mechanism remains inactivated when holding or grasping or using device to perform a venap uncture) 3. Once the safety mechanism is activated, no part of the needle is accessible. (The cover or shield covers the entire needle) 4. Once the safety mechanism is activated, the device cannot be reused. (The cover or shield leaves the device wit h no ability to uncover the needle and reuse the needle) 5. Product is compatible with luer-loc and slip tip syringes, regardless of manufacturer. (The hub of the safety needle will connect with a luer-loc and slip tip syringe). Phase III: Pricin g Analysis Process After the clinical/performance evaluation is completed and analyzed, all vendors who participated in the clinical/performance evaluation will be contacted to submit their lowest pricing quotes (as well as product cross-reference d ata) based on committed volume of 80% of the total Regional requirement. Vendors will be provided seven calendar days to submit their price quotes in a prescribed format via email. Price quotes must be received by 4:00 p.m. Hawaii Standard Time (HST) 7th c alendar day. Failure to respond within this timeframe or failure to submit incentive discounts from their DAPA prices will result in the vendor being disqualified from further consideration/ participation. The Region intends to evaluate quotes and select a vendor or vendor(s), without discussions as noted above. However, the Region reserves the right to conduct discussions and request revised pricing, if determined to be necessary. Clinical/performance and technical/company factors will be weighted more heavily than price. As the technical and clinical evaluation results become more equal, price will become more important. Pricing will be evaluated based on best value to the government and will be based on a committed volume for a two-year period wit h possible one-year option periods (not to exceed 5 years). The following elements will be considered in the pricing analysis: (1) Impact of RIA prices on the Region (Post-Standardization Costs), (2) Potential Cost Avoidance, (3) Impact of Unmatched Lines , and (4) Consideration of stockage keeping units (SKUs) by each vendor. Due to the potential for Base DAPA prices to be inflated, the Impact of RIA prices on the Region is considered more important than other pricing elements.
- Place of Performance
- Address: Pacific Regional Contr Ofc TAMC ATTN: MCAA PC BLDG 160, 160 Krukowski Road Honolulu HI
- Zip Code: 96859-5000
- Country: US
- Zip Code: 96859-5000
- Record
- SN01524973-W 20080307/080305224941 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |